[HTML] mdpi.com

[HTML][HTML] Cardiovascular and renal effectiveness of GLP-1 receptor agonists vs. other glucose-lowering drugs in type 2 diabetes: a systematic review and meta-analysis …

I Caruso, A Cignarelli, GP Sorice, A Natalicchio… - Metabolites, 2022 - mdpi.com
Cardiovascular outcome trials (CVOT) showed that treatment with glucagon-like peptide-1
receptor agonists (GLP-1RA) is associated with significant cardiovascular benefits …
被引用次数：45 相关文章

Cardiovascular and Renal Effectiveness of GLP-1 Receptor Agonists vs. Other Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Meta-Analysis …

I Caruso, A Cignarelli, GP Sorice… - …, 2022 - pubmed.ncbi.nlm.nih.gov
Cardiovascular outcome trials (CVOT) showed that treatment with glucagon-like peptide-1
receptor agonists (GLP-1RA) is associated with significant cardiovascular benefits …

Cardiovascular and Renal Effectiveness of GLP-1 Receptor Agonists vs. Other Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Meta-Analysis …

I Caruso, A Cignarelli, GP Sorice, A Natalicchio… - …, 2022 - ricerca.uniba.it
Cardiovascular outcome trials (CVOT) showed that treatment with glucagon-like peptide-1
receptor agonists (GLP-1RA) is associated with significant cardiovascular benefits …
[HTML] nih.gov

[HTML][HTML] Cardiovascular and Renal Effectiveness of GLP-1 Receptor Agonists vs. Other Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Meta …

I Caruso, A Cignarelli, GP Sorice, A Natalicchio… - Metabolites, 2022 - ncbi.nlm.nih.gov
Cardiovascular outcome trials (CVOT) showed that treatment with glucagon-like peptide-1
receptor agonists (GLP-1RA) is associated with significant cardiovascular benefits …

Cardiovascular and Renal Effectiveness of GLP-1 Receptor Agonists vs. Other Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Meta-Analysis …

I Caruso, A Cignarelli, GP Sorice, A Natalicchio… - …, 2022 - search.proquest.com
Cardiovascular outcome trials (CVOT) showed that treatment with glucagon-like peptide-1
receptor agonists (GLP-1RA) is associated with significant cardiovascular benefits …

Cardiovascular and Renal Effectiveness of GLP-1 Receptor Agonists vs. Other Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Meta-Analysis …

I Caruso, A Cignarelli, GP Sorice, A Natalicchio… - 2022 - agris.fao.org
Cardiovascular outcome trials (CVOT) showed that treatment with glucagon-like peptide-1
receptor agonists (GLP-1RA) is associated with significant cardiovascular benefits …

Cardiovascular and Renal Effectiveness of GLP-1 Receptor Agonists vs. Other Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Meta-Analysis …

I Caruso, A Cignarelli, GP Sorice, A Natalicchio… - Metabolites, 2022 - europepmc.org
Cardiovascular outcome trials (CVOT) showed that treatment with glucagon-like peptide-1
receptor agonists (GLP-1RA) is associated with significant cardiovascular benefits …

Cardiovascular and Renal Effectiveness of GLP-1 Receptor Agonists vs. Other Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Meta-Analysis …

I Caruso, A Cignarelli, GP Sorice… - Metabolites (2218 …, 2022 - search.ebscohost.com
Cardiovascular outcome trials (CVOT) showed that treatment with glucagon-like peptide-1
receptor agonists (GLP-1RA) is associated with significant cardiovascular benefits …

Cardiovascular and Renal Effectiveness of GLP-1 Receptor Agonists vs. Other Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Meta-Analysis …

I Caruso, A Cignarelli, GP Sorice, A Natalicchio… - Metabolites, 2022 - europepmc.org
Cardiovascular outcome trials (CVOT) showed that treatment with glucagon-like peptide-1
receptor agonists (GLP-1RA) is associated with significant cardiovascular benefits …